Holsts laboratory played a central role in characterizing the active intestinal form of GLP-1, demonstrating its therapeutic potential in diabetes, as well as obesity treatment, and developing early drug analogs
[DOI] [PMC free article] [PubMed] [Google Scholar] 785.Carlsson LMS, Sjholm K, Jacobson P, et al
These include self-monitoring (tracking food intake, weight, and activity), identifying and managing triggers for overeating, developing coping strategies for emotional eating, and building a supportive environment
Both liraglutide and semaglutide show similar weight loss benefits
However, researchers also noticed an intriguing side effect: weight loss
Dosing Conversations: What Patients Should Understand Dosing is usually increased gradually to balance benefit and tolerability